Intec Pharma expects to earn revenue from Parkinson’s pill in 2019

Intec Pharma, which is conducting a late stage trial for its long-lasting pill to treat Parkinson’s disease, expects to begin earning revenue from the program in 2019, Reuters reports, citing CEO Jeffrey Meckler.” I feel very comfortable that we have an approvable program here. I would like to see as big an effect size as possible, but there is commercial viability at any effect size. I hope next year we will be able to monetize value out of the Parkinson’s program, whether that is the sale of the company, sale of the program or a license partnership,” said Meckler, who said assuming a 10% market share, “We have a drug that is worth more than $300M a year.”
https://thefly.com/landingPageNews.php?id=2834651